Clinical Trials in Albuquerque, NM
Here are the 6 most popular medical studies in albuquerque
Behavioral Intervention
Fitbit for Breast Cancer
Recruiting1 award
Albuquerque, New Mexico
This trial aims to find out if being more active throughout the day can help improve chronic pain and other symptoms in breast cancer survivors after surgery. Being physically active is important for overall health and may help reduce
Category 1 (biospecimens, surveys, interviews) for Cancer
Recruiting1 award
Albuquerque, New Mexico
This trial is looking at ways to recruit American Indians from Southwestern Tribal Nations for cancer genome sequencing. American Indians in this region have higher rates of certain types of cancer, and they may also have shorter
Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor
Dapagliflozin +1 More for Type 2 Diabetes
Recruiting2 awardsPhase 3
Albuquerque, New Mexico
This trial will compare the safety and effectiveness of orforglipron and dapagliflozin in helping people with type 2 diabetes control their blood sugar levels. The trial will last for about
Popular filter options for albuquerque trials
Clinical Trials With No Placebo
View 99 medical studies that do not have a placebo group.
Behavioural Intervention
Making it Work Systemic Sclerosis for Systemic Scleroderma
Recruiting1 award
Albuquerque, New Mexico
This trial is testing an online program called Making it Work Systemic Sclerosis to see if it helps people with Systemic Sclerosis stay employed and feel more confident at work. Participants will either receive the
Behavioural Intervention
ePACE +1 More for Substance Abuse
Recruiting1 award
Albuquerque, New Mexico
"This trial aims to compare two different web-based intervention programs, ePACE and eFACE, for adolescents with substance use and common behavioral problems. The goal is to see if these interventions are more effective than
Observational Group for Neonatal Abstinence Syndrome
Recruiting1 award4 criteria
Albuquerque, New Mexico
Substance abuse during pregnancy is on the rise through both prescribed and illicit use of controlled substances, which has increased neonatal abstinence syndrome (NAS). The prevalence of opioid use during pregnancy has increased by 333% from 2013 to 2014 and continues to rise. Approximately 1 in 3 women were prescribed opioids during pregnancy from 2008 to 2012. In the US, NAS was diagnosed every 25 minutes in 2014. By 2019, it became every 15 minutes. Although there are medication-based interventions for the treatment of NAS, used in up to 80% of opioid-exposed infants, these treatments carry risks of toxicity and drug interactions. Despite the steep medical costs and the risks of treatment, current tools to assess the severity of NAS are subjective and suffer from examiner bias, resulting in poorer clinical outcomes, such as longer lengths of stay in the Neonatal Intensive Care Unit (NICU), for these babies. Studies have shown that continuous vital sign monitoring improves outcomes and decreases the length of stay in general practice. Preliminary machine learning models have been able to predict pharmacological treatment for Neonatal Opioid Withdrawal Syndrome (NOWS). This project will collect physiological and behavioral data of NAS patients to develop an AI algorithm and establish the advantages of continuous monitoring in NAS. The AI algorithm, processed by machine learning, will help predict NAS symptoms, automate scoring, and provide healthcare personnel with predictive analytics to guide suggested treatments.
Normal Cognition (NC) with at least 1 vascular risk factor for Dementia
Recruiting1 award10 criteria
Albuquerque, New Mexico
Biomarkers for Vascular Contributions to Cognitive Impairment and Dementia (MarkVCID) is an NIH-funded consortium dedicated to finding biomarkers involved in age-related thinking and memory problems. Alzheimer's disease and other dementias leave signatures on brain scans or in the blood called biomarkers. The MarkVCID study will measure a panel of candidate biomarkers in 1800 participants and watch them closely to see what they tell us about changes in brain function and risk of memory loss. Age-related problems in thinking and memory represent some of the greatest risks to public health in the US and globally. Diseases that affect small blood vessels in the brain have been shown to be major contributors to these changes. However, research and patient care can be held back by limited biomarkers that identify who should be treated. The MarkVCID Consortium includes 17 US medical centers, a Coordinating Center, an External Advisory Committee, and NIH leadership. Data and biospecimens collected as part of this research study will be stored in a research database and biorepositories, so that researchers can use this information to study brain function.
View More Albuquerque Trials
See another 81 medical studies focused on albuquerque.
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.